Related Experiment Video

Updated: Aug 17, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

The role of biological response modifiers in malignant melanoma

Marko B Lens1

  • 1University of Oxford, John Radcliffe NHS Trust, Oxford, UK.

Expert Opinion on Biological Therapy
|December 4, 2003
PubMed

Insights

Interferon-alpha (IFN-alpha) shows inconsistent results for adjuvant melanoma treatment, while interleukin-2 (IL-2) has modest effects but significant toxicity. Further research is needed for biological response modifiers in melanoma management.

Area of Science:

  • Oncology
  • Immunology
  • Dermatology

Background:

  • Melanoma treatment requires effective systemic therapies.
  • Biological response modifiers (BRMs) like IFN-alpha and IL-2 are explored for melanoma management.

Purpose of the Study:

  • To review existing data on the role of IFN-alpha and IL-2 in melanoma management.
  • To evaluate the efficacy and toxicity of these BRMs.

Main Methods:

  • Review of eight prospective controlled Phase III trials for IFN-alpha therapy.
  • Analysis of data on IL-2 antitumour activity and toxicity.
  • Discussion of combination therapies (chemotherapy and BRMs).

Main Results:

  • IFN-alpha trial results are heterogeneous and inconsistent, leaving its role in adjuvant treatment undefined.
  • IL-2 demonstrates modest antitumour activity (approx. 15% response rate) but causes significant toxic effects.
  • Impact of combination therapies on tumour response and survival is discussed.

Conclusions:

  • The role of IFN-alpha in adjuvant melanoma treatment remains uncertain due to inconsistent trial outcomes.
  • High-dose IL-2 has limited efficacy and considerable toxicity, necessitating careful consideration.
  • Further investigation into BRMs and combination therapies is warranted for improved melanoma management.

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.